Biotech Sponsors Dominate 2024 FDA Approvals | Evaluate
Biotech FDA approvals accounted for two thirds of the 2024 total – a big shift from 2023. We investigate the drivers and challenges for small players going it alone.| Evaluate
Biotech FDA approvals accounted for two thirds of the 2024 total – a big shift from 2023. We investigate the drivers and challenges for small players going it alone.| Evaluate
2024 Review of Pharma - Analysis of the state of dealmaking, investment & stock price performance of the biopharma sector in 2024| Evaluate
Join us for an insightful session, as we tackle the common challenges associated throughout the Long-Range Planning cycle.| Evaluate
What does 2025 have in store for pharma forecasting teams? We explore the evolving role of forecasting teams in the pharmaceutical industry.| Evaluate
